至此， 这场长达八年、打了600余场官司的商标侵权案终于随着拉夫劳伦的终审胜诉而落幕 。 北京高院此次作出的终审判决延续了2021年广州知识产权法院对"RalphLauren"商标进行"驰 名商标"认定，就已经体现出的对于拉夫劳伦旗下商标知名度的认可及保护倾向。 此前，北京知识产权法院已就此案作出一审判决， 先行认定"POLO"商标依法构成"驰名商 标"，判决拉夫劳伦胜诉 。被告国家知识产权局及第三人广州爱驰公司均不服一审判决，上诉 至北京高院。在终审判决中，北京高院维持了北京知识产权法院所作认定，重申了"POLO"商 标已构成驰名商标之事实，并认定诉争商标的存在与使用可能将误导相关公众，减弱、淡 化"POLO"商标的显著性，损害拉夫劳伦公司的利益。 去年12月，该案曾在社交媒体上引起广泛讨论，核心争议在于"POLO"当前已成为服装品类， 且可以作为英文实词进行日常使用。 记者丨 高江虹 编辑丨高梦阳 9月26日，拉夫劳伦公司宣布 在中国知识产权维权领域取得里程碑式胜利 。 近日，北京市高级人民法院（以下简称"北京高院"）对拉夫劳伦就广州爱驰公司旗下"POLO POLO CLUB" 商 标 无 效 宣 告 请 ...

会上，江门市市场监管局介绍了通过"益企维"平台在跨区域协作、执法能力提升等方面取得的成效，特 别是"新会陈皮"地理标志产品通过"益企维"知识产权保护联盟机制获得的保护成效。依托这一全国性协 作机制，不仅拓展了知识产权保护的覆盖面，还提升了案件办理效率和执法水平。 为深化知识产权跨区域跨部门协同保护，系统总结"益企维"创新实践经验，探索保护协作新模式新路 径，进一步优化营商环境，在第十四届中国知识产权年会期间，由福建省漳州市市场监督管理局主办 的"益企维"知识产权协同保护机制创新推进会在北京成功召开。江门市市场监督管理局作为协作单位代 表在会上作交流发言。 下一步，江门市市场监管局将继续依托"益企维"知识产权联盟协作机制，深化与各成员单位的沟通协 作，共同推动知识产权协同保护工作创新发展，为优化营商环境提供有力支撑。 据悉，"益企维"机制目前已覆盖全国19个省区的56个地市63个成员单位，成为知识产权保护领域重要的 协作平台。各成员单位通过该机制积极开展地理标志等知识产权保护协作，累计办理案件225件，为企 业节约维权成本2300多万元。 ...

Core Viewpoint - Shenzhen SanTai E-commerce Co., Ltd. is benefiting from the depreciation of the RMB and is actively developing AI-driven tools for risk detection in cross-border e-commerce [2][3]. Company Overview - Shenzhen SanTai E-commerce Co., Ltd. was established on January 7, 2008, and is located in Nanshan District, Shenzhen, Guangdong Province. The company primarily engages in cross-border e-commerce retail and logistics [7]. - The company's revenue composition includes 76.14% from cross-border e-commerce product sales, 23.80% from logistics sales, and minimal contributions from technology services and other businesses [7]. Business Developments - The company launched its AI-based intellectual property risk detection tool "RuiGuan·ERiC" for trial use on September 28, 2023, aimed at providing flexible and cost-effective risk monitoring solutions [2][3]. - The company is also developing an AIGC project that utilizes Stable Diffusion for generating high-quality images, enhancing operational efficiency and reducing production costs [2]. Financial Performance - For the first half of 2025, the company reported a revenue of 827 million yuan, representing a year-on-year growth of 3.27%, while the net profit attributable to shareholders decreased by 48.75% to 23.26 million yuan [8]. - As of September 19, 2023, the number of shareholders increased to 30,500, with an average of 7,192 circulating shares per person [8]. Market Position - The company operates in the cross-border e-commerce sector, which is part of the broader internet retail industry. It is positioned within several concept sectors, including intellectual property, express delivery, and small-cap stocks [8]. - The company's overseas revenue accounted for 99.98% of its total revenue, benefiting from the depreciation of the RMB [3].

近日，厦门金达威集团股份有限公司及子公司厦门金达威生物科技有限公司收到国家知识产权局颁发的 发明专利证书。发明名称为"一种辅酶Q10油剂及其制备方法和应用"，专利号ZL202310111297.8，申请 日为2023年，专利权期限二十年，授权公告日为2025年。该发明涉及辅酶Q10技术领域，其辅酶Q10油 剂中辅酶Q10高含量下能稳定以分子形态存在、生物利用度高。此专利取得虽不对公司生产经营产生重 大影响，但利于技术创新、完善知识产权保护体系及增强核心竞争力。 ...

一直以来，当中国企业雄心勃勃地进军全球市场时，海外知识产权的"暗礁"往往防不胜防。尤其近年 来，杭州数字经济产业蓬勃发展，企业走出国门的知识产权需求日益多元化、精细化，对专利快速获 权、高效维权和全球化战略布局提出了更高要求。 2015年以来，以解决中国企业在"走出去"的过程中获取海外知识产权信息不足的问题为出发点，国家知 识产权局知识产权保护司推出"智南针"，面向国际化发展的企业和知识产权服务机构提供知识产权信息 服务。智南针网站涵盖了全球189个国家、地区、组织的1399部主要知识产权相关法律法规，提供了全 球20余个国家和地区的100余家海外知识产权服务机构信息，内嵌了国家海外知识产权纠纷应对指导中 心模块。 随着数字贸易的全球化发展，知识产权保护已成为企业国际竞争力的核心要素。2025年9月25至29日， 在第四届全球数字贸易博览会上，杭州市知识产权保护中心（以下简称"杭州保护中心"）在人工智能展 区首次独立设展，推出首席知识产权官——"海外版杭知AI"，打造"全时、全域、全链"的智慧知识产权 服务体系。这一举措不仅是杭州作为数字经济高地的创新实践，更是人工智能技术与知识产权保护深度 融合的生动写照。 ...

Core Viewpoint - Moleculin Biotech, Inc. has received a notice of allowance for a Canadian patent related to its drug candidate Annamycin, which is being developed for the treatment of hard-to-treat cancers, particularly acute myeloid leukemia and soft tissue sarcoma lung metastases [1][2][3] Group 1: Patent and Intellectual Property - The Canadian patent application covers methods for producing a preliposomal Annamycin lyophilizate with improved stability and high purity, with a base patent term extending until June 2040 [2] - The company is actively building its global intellectual property portfolio for Annamycin, which includes patents in the U.S., Europe, and other major jurisdictions [3] Group 2: Drug Development and Clinical Trials - Annamycin is positioned to be the first non-cardiotoxic anthracycline approved for use, with Fast Track Status and Orphan Drug Designation from the FDA for relapsed or refractory AML and STS lung metastases [3][4] - The company has initiated the MIRACLE Trial (MB-108), a pivotal Phase 3 trial evaluating Annamycin in combination with cytarabine for relapsed or refractory AML, following a successful Phase 1B/2 study [5] Group 3: Additional Pipeline and Research - In addition to Annamycin, the company is developing WP1066, an immune/transcription modulator targeting various cancers, and WP1122 for potential treatment of pathogenic viruses and certain cancer indications [6]

Core Viewpoint - The company Suhao Hongye experienced a decline in stock price and trading volume, indicating potential market challenges and investor sentiment issues [1] Company Overview - Suhao Hongye Co., Ltd. is located in Nanjing, Jiangsu Province, and was established on June 30, 1994, with its stock listed on September 1, 1997 [6] - The company's main business includes trade (import and export, domestic trade) and cultural services (cultural engineering, art management, cultural venue operations, and cultural creative product development and sales) [6] - The revenue composition is as follows: 98.45% from product sales, 1.05% from engineering projects and consulting services, and 0.51% from other sources [6] Financial Performance - For the first half of 2025, Suhao Hongye achieved a revenue of 3.919 billion yuan, representing a year-on-year growth of 10.73% [6] - The net profit attributable to the parent company was 26.2955 million yuan, showing a year-on-year increase of 34.72% [6] - The company has distributed a total of 503 million yuan in dividends since its A-share listing, with 74.0302 million yuan distributed in the last three years [7] Investment and Shareholding - The company holds a 16.31% stake in Hongye Futures, which is the second-largest shareholder, and Hongye Futures is listed on the Hong Kong Stock Exchange [2] - Suhao Hongye's subsidiary, Jiangsu Aitao Cultural Industry Co., Ltd., holds a 28% stake in Jiangsu Cultural Property Exchange Co., Ltd. [2] - The company invested 12 million yuan for a 24% stake in Jiangsu Hongrui Technology Investment Co., Ltd., the first venture capital firm in Jiangsu Province focused on the biopharmaceutical sector [2] Market Activity - On September 25, the stock price of Suhao Hongye fell by 1.65%, with a trading volume of 44.5315 million yuan and a turnover rate of 1.76%, resulting in a total market capitalization of 2.507 billion yuan [1] - The main capital flow showed a net outflow of 4.8943 million yuan, indicating a lack of strong buying interest from major investors [3][4] Technical Analysis - The average trading cost of the stock is 10.88 yuan, with recent reductions in shareholding but at a slowing rate [5] - The current stock price is near a resistance level of 10.42 yuan, suggesting potential for a pullback unless this level is breached, which could lead to an upward trend [5]

Group 1 - The core viewpoint of the news is that China has improved its ranking in the Global Innovation Index to 10th place, marking its first entry into the top ten globally, reflecting significant achievements in innovation-driven development strategies [1] - The Global Innovation Index evaluates the innovation ecosystem performance of 139 economies based on innovation input and output, showing that China's ranking has risen by 25 places since 2013 [1] - Nanjing ranks 15th in the global innovation cluster ranking and 5th among domestic clusters, based on metrics such as international patent applications, scientific publications, and new venture capital transactions [1] Group 2 - Nanjing's PCT application volume is 8,241.81, accounting for 0.63% of the global total, ranking 20th among the top clusters; its scientific publication volume is 136,094, representing 1.66% of the global total, ranking 5th; and the new venture capital transaction volume is 1,266, accounting for 0.54%, ranking 35th [2] - Nanjing has been recognized as a national model city for intellectual property protection and has achieved significant results in intellectual property strategy implementation, with patent quality indicators ranking first in the province for four consecutive years [2] - As of June 2025, Nanjing has a high-value invention patent ownership of 77.99 per ten thousand people, and the effective invention patents in the digital economy industry account for 62.9% of the total effective invention patents in the region, maintaining the top position in the province [2] Group 3 - Nanjing aims to leverage high-quality development of intellectual property to support high-quality economic and social development, focusing on becoming a leading city in intellectual property creation, utilization, protection, management, and service [3] - The city is committed to enhancing its intellectual property capabilities to better serve innovation-driven development and contribute to the modernization of Nanjing [3]

每经AI快讯，9月24日，科创新材发布公告称，公司近日收到国家知识产权局颁发的1项《实用新型专 利证书》。专利名称为"一种新能源坩埚运输用固定装置"。该专利的取得有助于提升公司的核心竞争 力，保护公司知识产权，并促进公司持续创新机制的形成。 ...

Core Viewpoint - Zhejiang Tailin Biotechnology Co., Ltd. has recently obtained five patent certificates, which will enhance its intellectual property protection and maintain its technological leadership in the industry [4]. Patent Acquisition Summary - The company’s wholly-owned subsidiary, Zhejiang Tailin Life Science Co., Ltd., has acquired five patents, including one invention patent. The details are as follows: - Patent for gas sterilization resistance detection device and method (Invention) [4] - Appearance patents for two types of plankton pretreatment equipment, a stationary sampler, and a compressed air microbiological testing instrument [4]. - The patents are expected to strengthen the company's innovation mechanism and core competitiveness, although they will not have a significant immediate impact on production and operations [4].